Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 14, 2025 06:45 ET | Source: BioNTech SE

BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung

BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den...
January 14, 2025 06:45 ET | Source: BioNTech SE

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a...
December 12, 2024 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has...
December 10, 2024 10:02 ET | Source: Association of American Physicians and Surgeons

COVID Non-pharmaceutical Interventions Were Harmful Authoritarian Overreach, according to Journal of American Physicians and Surgeons

Pandemic control measures for COVID likely did more damage than the disease itself. They were imposed without sound evidence, ignoring social consequences.
December 09, 2024 04:00 ET | Source: AKAMPION

tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients

- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...
December 06, 2024 09:15 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...
November 15, 2024 07:51 ET | Source: InflaRx N.V.

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...
October 28, 2024 08:05 ET | Source: BlueWillow Biologics

BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe

ANN ARBOR, Mich., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of intranasal vaccines, today announced that the company will...
October 22, 2024 05:00 ET | Source: Fraser Institute

Fraser Institute News Release: Job growth in government exceeded the private sector in 8 out of 10 provinces from 2019-23

VANCOUVER, British Columbia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- In eight of 10 provinces the rate of government job growth has been higher than the private sector, finds a new study published today...
September 20, 2024 08:10 ET | Source: BioNTech SE

Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron KP.2 angepassten COVID-19-Impfstoff in der Europäischen Union

Der an Omikron KP.2 angepasste COVID-19-Impfstoff wird nach Zulassung durch die Europäische Kommission für Personen ab 6 Monaten verfügbar seinDaten zeigten, dass der an Omikron KP.2 angepasste...